» Articles » PMID: 39677651

Cardiac Applications of CRISPR/AAV-Mediated Precise Genome Editing

Overview
Journal bioRxiv
Date 2024 Dec 16
PMID 39677651
Authors
Affiliations
Soon will be listed here.
Abstract

The ability to efficiently make precise genome edits in somatic tissues will have profound implications for gene therapy and basic science. CRISPR/Cas9 mediated homology-directed repair (HDR) is one approach that is commonly used to achieve precise and efficient editing in cultured cells. Previously, we developed a platform capable of delivering CRISPR/Cas9 gRNAs and donor templates via adeno-associated virus to induce HDR (CASAAV-HDR). We demonstrated that CASAAV-HDR is capable of creating precise genome edits within mouse cardiomyocytes at the neonatal and adult stages. Here, we report several applications of CASAAV-HDR in cardiomyocytes. First, we show the utility of CASAAV-HDR for disease modeling applications by using CASAAV-HDR to create and precisely tag two pathological variants of the titin gene observed in cardiomyopathy patients. We used this approach to monitor the cellular localization of the variants, resulting in mechanistic insights into their pathological functions. Next, we utilized CASAAV-HDR to create another mutation associated with human cardiomyopathy, arginine 14 deletion (R14Del) within the N-terminus of Phospholamban (PLN). We assessed the localization of PLN-R14Del and quantified cardiomyocyte phenotypes associated with cardiomyopathy, including cell morphology, activation of PLN via phosphorylation, and calcium handling. After demonstrating CASAAV-HDR utility for disease modeling we next tested its utility for functional genomics, by targeted genomic insertion of a library of enhancers for a massively parallel reporter assay (MPRA). We show that MPRAs with genomically integrated enhancers are feasible, and can yield superior assay sensitivity compared to tests of the same enhancers in an AAV/episomal context. Collectively, our study showcases multiple applications for precise editing of cardiomyocyte genomes via CASAAV-HDR.

References
1.
Earley L, Conatser L, Lue V, Dobbins A, Li C, Hirsch M . Adeno-Associated Virus Serotype-Specific Inverted Terminal Repeat Sequence Role in Vector Transgene Expression. Hum Gene Ther. 2020; 31(3-4):151-162. PMC: 7047122. DOI: 10.1089/hum.2019.274. View

2.
Ceholski D, Trieber C, Holmes C, Young H . Lethal, hereditary mutants of phospholamban elude phosphorylation by protein kinase A. J Biol Chem. 2012; 287(32):26596-605. PMC: 3411000. DOI: 10.1074/jbc.M112.382713. View

3.
Guo A, Song L . AutoTT: automated detection and analysis of T-tubule architecture in cardiomyocytes. Biophys J. 2014; 106(12):2729-36. PMC: 4070273. DOI: 10.1016/j.bpj.2014.05.013. View

4.
Eijgenraam T, Boukens B, Boogerd C, Schouten E, van de Kolk C, Stege N . The phospholamban p.(Arg14del) pathogenic variant leads to cardiomyopathy with heart failure and is unreponsive to standard heart failure therapy. Sci Rep. 2020; 10(1):9819. PMC: 7300032. DOI: 10.1038/s41598-020-66656-9. View

5.
Visel A, Minovitsky S, Dubchak I, Pennacchio L . VISTA Enhancer Browser--a database of tissue-specific human enhancers. Nucleic Acids Res. 2006; 35(Database issue):D88-92. PMC: 1716724. DOI: 10.1093/nar/gkl822. View